News & Views | Published:

The burden of faulty proofreading in colon cancer

Nature Genetics volume 45, pages 121122 (2013) | Download Citation

  • A Corrigendum to this article was published on 26 September 2013

This article has been updated

Our understanding of inherited risk factors for colorectal cancer (CRC) is incomplete. A new study reports the identification of germline CRC risk variants that adversely affect the proofreading function of DNA polymerases encoded by POLE and POLD1.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 05 September 2013

    In the version of the article initially published, reference 6 (J. Biol. Chem. 281, 4486–4494, 2006) should have been Genome 49, 403–410, 2006. Part of the associated sentence, "Alteration of this amino acid has been shown to lead to mutator phenotypes in yeast6," was revised to "Alteration of the equivalent residue in a related polymerase, POLD1, leads to mutator phenotypes in yeast6." In paragraph 4, alteration of a POLD1 residue in yeast, given as arginine, should have been asparagine. A sentence with an error in paragraph 7, "Similarly, tumors reported by Palles et al.4 that carried the POLE p.Leu424Val exonuclease-deficient germline variant also carried APC alterations," has been changed to state that the POLE p.Leu424Val variant alters an amino acid in the active site of the exonuclease domain. The revised sentence reads "Similarly, tumors reported by Palles et al.4 that carried the POLE p.Leu424Val germline variant, which maps to the active site of the exonuclease domain, also carried APC alterations." The legend for Figure 1 has been amended to include "Adapted with permission from ref. 5."

References

  1. 1.

    et al. CA Cancer J. Clin. 61, 69–90 (2011).

  2. 2.

    Annu. Rev. Pathol. 6, 479–507 (2011).

  3. 3.

    Drug Discov. Today Dis. Mech. 4, 293–300 (2007).

  4. 4.

    et al. Nat. Genet. 45, 136–144 (2013).

  5. 5.

    , & Semin. Cancer Biol. 20, 281–293 (2010).

  6. 6.

    , , , & Genome 49, 403–410 (2006).

  7. 7.

    et al. Proc. Natl. Acad. Sci. USA 106, 17101–17104 (2009).

  8. 8.

    TCGA. Nature 487, 330–337 (2012).

  9. 9.

    et al. Nature 488, 660–664 (2012).

Download references

Author information

Affiliations

  1. Somasekar Seshagiri is at Genentech Inc., Department of Molecular Biology, South San Francisco, California, USA.

    • Somasekar Seshagiri

Authors

  1. Search for Somasekar Seshagiri in:

Competing interests

The author is an employee of Genentech Inc. and holds Roche stocks.

Corresponding author

Correspondence to Somasekar Seshagiri.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ng.2540

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing